Mild-to-Moderate Atopic Dermatitis Market Set for Steady Growth Through 2035 as Non-Steroidal Topicals and Targeted Biologics Redefine Early-Stage Care, Thelansis Reports

Thelansis Knowledge Partners releases new market outlook, epidemiology, competitive landscape, and forecast report on Mild-to-Moderate Atopic Dermatitis covering the US, EU5, Japan, and China (2026-2036)
Thelansis Knowledge Partners LLP, a global life sciences market research and consulting firm, has announced the release of its latest syndicated report, "Mild-to-Moderate Atopic Dermatitis - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036." The report arrives at a pivotal moment for the atopic dermatitis (AD) treatment landscape, as a wave of non-steroidal topicals, newly updated clinical guidelines, and an expanding biologics pipeline are reshaping how physicians manage patients earlier in the disease course, well before they ever progress to moderate-to-severe therapy.

EXECUTIVE SUMMARY
Atopic dermatitis remains one of the most common chronic inflammatory skin conditions worldwide, and mild disease continues to make up the largest share of the diagnosed population in the US alone; mild AD accounts for close to 14.7 million cases, ahead of moderate and severe subtypes. Yet for years, this segment has been comparatively underserved, with care leaning heavily on topical corticosteroids and calcineurin inhibitors. That is now changing.
The global atopic dermatitis treatment market, spanning all severities, is projected to grow at a CAGR of roughly 6-7% through the mid-2030s, and mild-to-moderate disease is an increasingly active part of that story. A steady cadence of FDA approvals tapinarof, roflumilast, topical ruxolitinib, and most recently difamilast has given physicians a genuine steroid-sparing toolkit for the first time, while updated American Academy of Dermatology (AAD) guidance is actively steering prescribing patterns toward these newer agents.
Thelansis's new report unpacks this shift in detail, offering a data-backed view of epidemiology, current and emerging therapies, competitive dynamics, and a 10-year, patient-based market forecast across eight major markets: the US, Germany, France, Italy, Spain, the UK, Japan, and China.

Request a free sample of Thelansis' Mild-to-Moderate Atopic Dermatitis Market Outlook and Forecast Report to secure the complete 2026-2036 forecast, exclusive KOL insights, and competitive pipeline data across the 8 Major Markets: https://thelansis.com/reports/mild-to-moderate-atopic-dermatitis-market-outlook-forecast-2026-to-2036/

KEY EMERGING PLAYERS
The mild-to-moderate AD pipeline has broadened well beyond biologics for severe disease, with several companies now developing agents specifically suited to earlier-stage, steroid-sparing use:
• Otsuka Pharmaceutical - difamilast, a topical PDE4 inhibitor, received FDA marketing authorization for mild-to-moderate AD, expanding the non-steroidal topical class.
• Sanofi - amlitelimab (anti-OX40L), with late-breaking Phase 3 data presented at the AAD Annual Meeting, signaling ambitions to extend targeted biology into earlier disease stages.
• Connect Biopharma - rademikibart (IL-4Rα blocker), advancing into Phase III following FDA alignment on its chronic AD development pathway.
• LEO Pharma - temtokibart (IL-22RA1 blocker), part of a new wave of pathway-specific candidates aimed at broader patient segments, including milder presentations.
• Union Therapeutics - orismilast, an oral PDE4 inhibitor in development, offering a potential systemic option positioned ahead of biologic escalation.
• Additional pipeline activity around TSLP- and OX40-pathway candidates continues to reflect sustained industry interest in earlier intervention and steroid-sparing maintenance therapy.

Request a sample report for an in-depth analysis of key emerging players, pipeline staging, and mechanisms of action in Mild-to-Moderate Atopic Dermatitis: https://thelansis.com/reports/mild-to-moderate-atopic-dermatitis-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mmad_mo

KEY CURRENT THERAPIES / STANDARD OF CARE
Management of mild-to-moderate AD has traditionally centered on barrier repair and intermittent anti-inflammatory control, but the standard of care has genuinely diversified over the past two years:
• Emollients & barrier repair - foundational to all AD care, strongly recommended across every severity band and age group.
• Topical corticosteroids (TCS) - remain first-line for flares, valued for efficacy, cost, and accessibility, though long-term use is limited by patient and caregiver hesitancy.
• Topical calcineurin inhibitors - tacrolimus and pimecrolimus, preferred for sensitive areas and proactive maintenance.
• Crisaborole (Eucrisa) - a PDE4 inhibitor ointment approved for patients as young as 3 months.
• Roflumilast cream (Zoryve) - recently earned a strong AAD recommendation and doubled the likelihood of achieving EASI-75 versus vehicle in pooled trials.
• Tapinarof cream (Vtama) - a first-in-class aryl hydrocarbon receptor agonist supported across mild, moderate, and severe disease.
• Ruxolitinib cream (Opzelura) - a topical JAK1/JAK2 inhibitor delivering rapid itch relief, now recommended down to age 2.
• Delgocitinib ointment (Corectim) - an additional topical JAK option expanding physician choice in select markets.

KEY MARKET DRIVERS / TRENDS
• Updated clinical guidelines - the AAD's focused adult update and its first-ever pediatric AD guidelines (2026) give strong, evidence-based recommendations to tapinarof, roflumilast, ruxolitinib, and other non-steroidal agents, directly influencing prescribing behavior.
• High and stable disease prevalence - mild AD remains the largest diagnosed subtype, sustaining a broad addressable treatment population across all eight covered markets.
• "Steroid phobia" and long-term safety concerns - growing patient and caregiver reluctance to use chronic topical corticosteroids continues to push demand toward non-steroidal alternatives suitable for maintenance use.
• Earlier intervention philosophy - physicians are increasingly favoring proactive, steroid-sparing regimens over reactive flare management, extending treatment duration and product utilization.
• Pipeline diversification - new mechanisms (PDE4, AhR agonism, topical JAK, IL-22RA1, IL-4Rα) are lowering the therapeutic bar for entering earlier-stage disease, intensifying competition.
• Broadening pediatric access - several newer topicals are now approved or under review for use in children as young as 2, unlocking a historically underserved patient segment.

Translate these macro drivers into a competitive advantage. Request the Thelansis Mild-to-Moderate Atopic Dermatitis sample report to unlock granular pipeline analysis, deal tracking, and market forecasts: https://thelansis.com/reports/mild-to-moderate-atopic-dermatitis-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mmad_mo

KEY UNMET NEED & KOL EXPECTATIONS
Despite meaningful progress, dermatologists and payers interviewed for the report continue to flag several gaps that emerging therapies have yet to fully close:
• Durable, long-term maintenance options that patients are comfortable using continuously without corticosteroid-related fatigue or anxiety.
• Faster, more consistent itch control, given how disproportionately pruritus drives quality-of-life impact even in milder disease.
• Simplified treatment algorithms as the growing number of non-steroidal choices creates genuine sequencing and selection complexity for prescribers.
• Stronger pediatric-specific evidence, particularly long-term safety data to support confident use in younger age groups.
• Improved affordability and payer access, so that non-steroidal topicals are not reserved only for patients who fail conventional therapy first.

COMMERCIAL OPPORTUNITY
For pharmaceutical and biotech companies developing or commercializing mild-to-moderate AD therapies, Thelansis's report is designed to support strategic decision-making across the product lifecycle. It delivers:
• A 10-year, patient-based market forecast (2026-2036) across the US, EU5, Japan, and China, validated through top-down sales cross-checks.
• Epidemiology modeling covering incidence, prevalence, diagnosis rates, and drug-treated populations, delivered as an interactive Excel-based tool.
• Competitive landscape and KOL insights on current and late-stage emerging therapies, including launch expectations and positioning.
• Unmet need and target product profile (TPP) analysis, benchmarking pipeline assets against physician and payer expectations.
• Regulatory and reimbursement insights by country, supporting market access planning.

Access the complete Mild-to-Moderate Atopic Dermatitis market outlook and forecast report to explore the evolving market and future commercial opportunities: https://thelansis.com/reports/mild-to-moderate-atopic-dermatitis-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mmad_mo

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.